BUZZ-Veru rises after US FDA backs obesity drug combo plan
I'm PortAI, I can summarize articles.
Veru's shares rose 6.6% after the FDA supported its plan to test the obesity drug enobosarm with GLP-1 weight-loss medicines. A mid-stage trial will start next year, enrolling 200 patients aged 65+ to track weight changes over 72 weeks. The FDA agreed that additional weight loss or benefits in strength and function could lead to approval if confirmed in larger studies. Veru's stock is down 62.5% YTD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments